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AJH 2006; 19:1190–1196Achieving optimal outcomes in the treatment of hyperten-
sion—a prevalent and largely asymptomatic disease—ne-
cessitates that patients take their medications not only
properly (medication adherence) but also continue to do so
throughout long-term treatment (persistence). However,
poor medication-taking behavior is a major problem
among patients with hypertension, and has been identified
as one of the main causes of failure to achieve adequate
control of blood pressure (BP). In turn, patients with
hypertension who have uncontrolled BP as a result of their
poor medication-taking behavior remain at risk for serious
morbidity and mortality (eg, stroke, myocardial infarction,
and kidney failure), thereby accounting for a significant
cost burden through avoidable hospital admissions, pre-
mature deaths, work absenteeism, and reduced productiv-
ity. Improving medication-taking behavior during
antihypertensive therapy therefore represents an important
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doi:10.1016/j.amjhyper.2006.04.006potential source of health and economic improvement.
Whereas many factors may contribute to poor medication-
taking behavior, the complexity of dosage regimens and
the side effect profiles of drugs probably have the greatest
therapy-related influence. Central to any strategy aimed at
improving outcomes for patients with hypertension, there-
fore, are efficacious antihypertensive agents that facilitate
good medication-taking behavior through simplified dos-
ing and placebo-like tolerability, along with the develop-
ment of programs to detect poor medication adherence and
to support long-term medication persistence in daily
practice. Am J Hypertens 2006;19:1190–1196 © 2006
American Journal of Hypertension, Ltd.
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ior.T he optimal prevention and treatment of ill healthrequires efficacious and well tolerated medications.However, such benefits cannot be realized if pa-
tients take their medication incorrectly or not at all, either
intentionally or unintentionally. The problem of poor med-
ication-taking behavior is apparent for symptomatic con-
ditions such as asthma or epilepsy, in which patients are
generally aware that the consequences of not closely fol-
lowing their drug regimens or withdrawing from treatment
altogether could result in serious adverse outcomes or
even death.1 However, this problem is particularly rele-
vant for the treatment of chronic asymptomatic diseases
such as hypertension, in which no immediate physical
symptoms resulting from missing doses, on either an oc-
casional or permanent basis, are apparent. In the longer
term, however, the inadequate control of elevated blood
pressure (BP) that culminates from poor medication-tak-
ing behavior during antihypertensive therapy means that
patients remain at significant risk for costly micro- and
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tre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.macrovascular complications (eg, stroke, myocardial in-
farction, and kidney disease) that can result in premature
mortality. In view of the growing prevalence of hyperten-
sion in the United States and other industrialized nations,
and increasing awareness of the need for effective BP
control,2,3 medication-taking behavior is becoming an in-
creasingly important aspect of hypertension management.
The aim of this review, therefore, is to discuss the issue of
medication-taking behavior, including terms and defini-
tions, the scope of the problem, reasons for and conse-
quences of the problem, as well as methods to improve
medication adherence and persistence in the growing pop-
ulation of patients with hypertension.
Terminology and Measurement
of Medication-Taking Behavior
Medication-taking behavior encompasses both medication
adherence and persistence, terms for which distinct defi-
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be defined as the extent to which a patient’s behavior, with
respect to taking medication, corresponds with agreed
recommendations from a healthcare provider.1 “Medica-
tion persistence” represents the accumulation of time from
initiation to discontinuation of therapy (Fig. 1). The term
“concordance” has been suggested as a broader term be-
yond adherence, encompassing shared goals in which pa-
tients’ medication-taking behavior matches healthcare
recommendations.4,5 Persistence is measured in terms of
time, whereas medication adherence is reported in terms of
the percentage of prescribed doses taken per defined pe-
riod of time. An important point to consider is that med-
ication adherence is a dynamic parameter that is not stable
over time. This is eloquently demonstrated by partial ad-
herence, for example, in patients with highly variable
medication adherence whose medication-taking behavior
often improves around the time of a scheduled clinic visit
but declines thereafter.6 Recognition of the dynamic na-
ture of medication adherence is therefore important when
considering ways in which poor medication-taking behav-
ior could be improved.
Various methods are used to measure medication ad-
herence, ranging from patient self-reporting to sophisti-
cated electronic monitoring. These measures are generally
grouped into three categories: subjective (eg, patient in-
terviews), direct (eg, analysis of drug levels in bodily
fluids), and indirect (eg, pill counts, prescription refills,
electronic monitoring of medication use). Subjective eval-
uations, such as the four-item Morisky Medication Taking
Behavior Scale,7 are simple and practical approaches to
determining medication adherence. In that study, for ex-
ample, patients who answered “yes” to questions such as
“Do you ever forget to take your medicine?” and “Are you
careless at times about taking your medicine?” were less
likely to have their BP under control. An eight-item in-
strument that could be easily administered to identify
problems with medication-taking behavior has since been
developed by Morisky et al (manuscript in development),
FIG. 1. Aspects of medication-taking behavior.and was found to have good concurrent and predictivevalidity. However, self-reporting of medication adherence
may often be inaccurate because of difficulties with patient
recall, attempts to please the healthcare provider, or a
combination of these factors.8 Physicians also tend to
overestimate medication adherence in their patients, with
one early study reporting poor correlation between the
physician estimate of adherence and objective pill counts.9
Moreover, studies have demonstrated that the physician’s
judgment on patients’ adherence has low sensitivity
(40%) but good specificity (90%), suggesting that
physicians are good at detecting good adherence but not
poor or partial adherence.10,11
For some drugs, such as antiepileptic agents, adherence
may be determined from the measurement of drug levels
in bodily fluids (eg, blood, urine, saliva). This approach is
generally considered to be more reliable than subjective
measures of medication adherence12 but is not feasible in
most practice settings and tests can be costly. Moreover,
interpretation is complicated by drug pharmacokinetics; if
the patient takes the dose just before a physician visit, for
example, the results may be misleading. Interindividual
differences in drug absorption and metabolism can also
lead to differences in drug levels among those who show
similar medication adherence. Finally, drug assays are
unable to show whether the patient took the appropriate
dose at the proper time as prescribed.
Indirect methods are the most common approach to
measuring medication adherence. For example, counting
the number of unused pills remaining after a given time,
and subtracting this from the original quantity dispensed,
is a simple and practical method of estimating the quantity
of medication presumably used by the patient. However,
patients may have discarded some tablets, and counting
inaccuracies are common; therefore pill counting can often
result in an overestimation of medication adherence.13 In
addition, important information such as the pattern of
missed doses is not captured using this approach. Other
indirect methods include the analysis of prescription refill
data from pharmacy database records. One technique in-
volves calculation of the medication possession ratio, de-
fined as the number of days’ supply of drug obtained
during a specific time period.14 For example, if the pa-
tient’s prescription was for 30 days of therapy but the
subsequent prescription was not filled for another 7 days,
then the medication possession ratio would be 0.81 (ie,
30/37). Pharmacy refill data can also be used to measure
medication persistence, in terms of the time between ini-
tiation and discontinuation of therapy. However, prescrip-
tion refill records are only a valid source of information
about medication-taking behavior when the database is
complete; if the patient uses a pharmacy not linked to the
database, then it can lead to incomplete and erroneous
calculations.
Electronic monitoring devices, such as the Medication
Event Monitoring System ([MEMS] Aprex Corporation,
Fremont, CA), can be used to provide accurate and de-
tailed information on medication-taking behavior.15,16 Al-
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research setting, an advantage of these devices is that the
actual dates and times of events are recorded; this infor-
mation can subsequently be retrieved and interpreted by
the healthcare provider during consultation with the pa-
tient. In turn, electronic monitors can help to address
problems with medication-taking behavior.17–19 Although
there is no certainty about the actual intake of the medi-
cation by the patient, these devices have been shown to
have superior sensitivity compared with other methods of
determining medication adherence.16
Medication-Taking Behavior
During Antihypertensive Therapy
Numerous large-scale clinical trials, such as the Antihy-
pertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT)20 and the Hypertension
Optimal Treatment (HOT) trial,21 have demonstrated the
benefits of BP control to reduce cardiovascular mortality
and morbidity in patients with hypertension. In the HOT
trial, for example, which involved 18,790 patients with
hypertension, the lowest incidence of major cardiovascular
events was found to occur when antihypertensive therapy
decreased diastolic BP to an average of 82.6 mm Hg.21 Yet
there is still a large discrepancy between results from
clinical trials and the low rates of BP control within the
community.22–25 This gap between everyday clinical prac-
tice and clinical trials is probably largely explained by
differences in medication-taking behavior, in that clinical
trials tend to select for highly motivated patients whose
medication adherence and persistence is closely moni-
tored.11,26 Indeed, medication-taking behavior can vary
considerably in the hypertensive patient population rou-
tinely encountered. Results from a systematic review of
electronic monitoring studies, for example, indicated that
9% to 37% of patients had inadequate adherence to anti-
hypertensive medication,27 whereas a study based on self-
reported medication intake found that 35% of patients
were nonadherent.28 Others have reported nonadherence
rates in the range of 15% to 47% (mean 24%).29 The wide
range of adherence rates in published studies is presum-
Table 1. Potential reasons for poor medication-
taking behavior during antihypertensive therapy
Physician and patient factors
Cost of medication and related care
Instructions not clear to patient
Failure of physician to increase or change
therapy to achieve blood pressure goals
Inadequate or no patient education
Lack of involvement of patient in treatment plan
Therapy factors
Side effects of medication
Complexity of dosing regimenably a reflection not only of the range of methodologiesand antihypertensive agents that have been used but also
of the number and complexity of reasons for poor medi-
cation-taking behavior30 (Table 1).
Persistence with antihypertensive therapy is also prob-
lematic in routine care. In one study that analyzed phar-
macy refill data, persistence decreased in the first 6 months
after antihypertensive therapy was started and continued to
decline over the next 4 years. Among patients with newly
diagnosed hypertension, for example, 78% were persistent
at 1 year and only 46% at 4.5 years; patients with estab-
lished hypertension generally showed higher persistence
rates (97% and 82%, respectively)31 (Fig. 2). Bovet et al32
reported that among newly diagnosed hypertensive pa-
tients in a developing country, the percentage of patients
who had good adherence (as determined by electronic
monitoring) decreased from 46% to 26% between 1 month
and 12 months of follow-up. Other studies show that,
within 1 year, up to half of patients are no longer taking
their antihypertensive medication.33 Barriers to good med-
ication-taking behavior clearly tend to occur early in the
therapeutic course of antihypertensive therapy, emphasiz-
ing the need for regular reinforcement of the adherence
message by facilitators such as the following: 1) use of
reminders (as patient forgetfulness can be a frequent rea-
son for poor medication-taking behavior); 2) knowledge
about hypertension treatment and complications; and 3)
having social support and good doctor–patient communi-
cation.34,35
FIG. 2. Cumulative rate of persistence with antihypertensive ther-
apy, according to whether patients had established hypertension or
were newly diagnosed. Reproduced with permission from Ref. 31
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Medication-Taking Behavior
During Antihypertensive Therapy
Clearly, patients need to engage in good medication-taking
behavior during antihypertensive therapy to achieve good
control of their BP and decreased risk of cardiovascular
outcomes, a link that was established more than 40 years
ago.36 Some investigators have since suggested that poor
medication-taking behavior may not necessarily be asso-
ciated with resistance to antihypertensive treatment.27,37
For example, Nuesch et al37 reported that poor adherence
was no more prevalent among patients with poor BP
control than in patients without treatment resistance, lead-
ing to the conclusion that other factors independent of a
patient’s medication-taking behavior were more relevant
in explaining poor BP control. However, these investiga-
tors made no mention of the potential influence of treat-
ment side effects that may independently influence
medication-taking behavior, and they did not emphasize
the improvement in BP control upon monitoring of adher-
ence in their patients. The study by Wetzels et al,27 which
reviewed adherence findings reported in 30 studies of
antihypertensive medication treatment, also showed that
the relationship between medication-taking behavior and
BP control can be difficult to establish. The latter authors
restricted their analysis to studies that used electronic
monitoring, and in the majority of studies the patients were
aware that their adherence was being monitored. This may
have contributed to a trend toward higher adherence rates
and, in turn, better BP control, than in other studies.
Indeed, several authors reported that BP control was im-
proved (without changes in therapy) when a group of
patients with resistant hypertension were told that their
medication adherence was going to be electronically mea-
sured.18,19 In addition, in a recent study of 62 patients with
uncontrolled hypertension, use of MEMS was associated
with a significantly greater proportion of patients achiev-
ing target systolic BP after 4 months compared with pa-
tients whose adherence was monitored according to usual
care.38 If the majority of patients achieve a high rate of
adherence, a direct correlation between BP control and
medication-taking behavior may be difficult to show. It is
also important to note that difficulties exist in studying
patient adherence without informing patients that their
adherence is being monitored.
Elsewhere, most of the evidence suggests a correlation
between medication-taking behavior during antihyperten-
sive therapy and BP control, as highlighted by the study of
Elzubier et al,39 in which only 18% of nonadherent pa-
tients (as determined by returned tablet counts) achieved
good control of BP v 92% of those with good medication
adherence. Other studies have provided similarly convinc-
ing evidence. DiMatteo et al40 reported that patients who
adhered to their antihypertensive medication were three
times more likely to achieve good BP control than those
who were nonadherent. More recently, Halpern et al eval-uated the impact of medication-taking behavior on BP
outcomes during treatment with the angiotensin receptor
blocker (ARB) valsartan.41 Overall, patients with 90%
medication adherence (as determined by the medication
possession ratio) had lower average systolic BP and were
significantly more likely to achieve target BP goals than
patients with 90% adherence (96% v 81%; P  .0001).
Not surprisingly, the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) has identified
poor medication-taking behavior (specifically, adherence)
as one of the main causes of failure to control BP in
patients with hypertension.25 In turn, these patients remain
at high risk for cardiovascular disease42 including a higher
risk of stroke,43 and can be expected to account for a
significant cost burden through avoidable hospital admis-
sions, premature deaths, work absenteeism, and reduced
productivity.44,45 For example, a study of noninstitution-
alized Medicaid patients with hypertension found that
those with poor adherence consumed an additional $873
per patient in healthcare costs during the first year (1994
values), primarily because of increased hospital expendi-
tures.46 Consequently, adherence-based savings in medical
costs are driven primarily by reductions in hospitalization
rates at higher levels of medication adherence.47 Others
have shown that poor medication adherence causes an
average loss of 3.5 workdays per year in patients with
hypertension48 and can double the cost per quality-ad-
justed life-year gained,49 which emphasizes the economic
impact of poor adherence. Improving medication-taking
behavior during antihypertensive therapy could therefore
represent an important potential source of health and eco-
nomic improvement.50 Further research is warranted.
Improving Medication-
Taking Behavior During
Antihypertensive Therapy
Improving medication-taking behavior requires consider-
ation of factors relating to patients, physicians and ther-
apy, the influences of which are not necessarily mutually
exclusive.
Patient and Physician Factors
No single intervention can robustly enhance medication-
taking behavior because many variables affect the patient’s
decision to take or not take a drug. There is an urgent need,
therefore, for comprehensive interventions that use cogni-
tive, behavioral, and affective strategies tailored to the
patient’s particular needs and based on objective and re-
liable assessments of medication-taking behavior.51–53 In
this regard, and based on the integral role of healthcare
professionals in patient education and self-management of
other diseases, education programs delivered by academic
nurse-counsellors in a primary care setting may encourage
hypertensive patients in their quest to attain and maintain
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with patients and their families to teach diabetes self-
management and help patients to gain control of their
disease,54 highlighting the benefits that can be achieved
through better communication between patients and
healthcare providers. For example, addressing the pa-
tient’s inability to perceive a benefit from the use of
therapy for an asymptomatic disease overcomes a power-
ful stimulus for poor medication-taking behavior55; studies
show that patients with hypertension who believe in the
necessity of medication are more likely to comply with
their therapy than those who do not.56 Multifaceted and
tailored interventions appear to be the most effective meth-
ods of improving medication-taking behavior during anti-
hypertensive therapy because they address the multiple
factors associated with the problem.57 However, these
techniques tend to be complex, expensive, and labor-
intensive,58 and they are not always effective in terms of
optimizing BP control.59,60
Although the emphasis has been on the patient’s role in
adherence and persistence issues, it is necessary to con-
sider physician-related factors that may also influence
medication-taking behavior. DiMatteo et al61 noted that
the behavior of the physician was a crucial element in
patients’ willingness and ability to follow treatment ad-
vice, as was closer attention to regular follow-up. This
finding is in agreement with earlier studies, which recog-
nized the importance of giving patients time and confi-
dence to ask their physician any questions about their
therapy and to discuss any problems relating to their
medication, as a means of overcoming barriers to poor
medication-taking behavior.62
Therapy Factors
It has been suggested that the complexity of the dosage
regimen and side effects are the therapy-related factors that
probably have the greatest influence.1,63 Indeed, a review
of studies that measured adherence using electronic mon-
itoring (across multiple indications) confirmed the inverse
relationship between adherence and the prescribed number
of doses per day,64 a relationship that is apparent in the
hypertension setting as well.37,65 Indeed, antihypertensive
agents that are dosed once daily are taken more regularly
than drugs that have to be taken more than twice daily.66
Patient surveys, which have attempted to determine the
reasons for poor medication-taking behavior, have repeat-
edly demonstrated that side effects associated with antihy-
pertensive drugs are also important in determining
adherence rates. Richardson et al,67 for example, noted
that fear of adverse effects, particularly among younger
patients and those in the early stages of treatment, was a
major barrier to good medication-taking behavior during
antihypertensive treatment. This threat to adherence oc-
curs when patients decide that the accompanying burden
of side effects outweighs the potential future benefits. The
risk of dose-dependent side effects, and the consequencesfor medication-taking behavior, is also probably one of the
important reasons for acceptance of inadequate BP control
by physicians. Indeed, studies show that physicians often
accept inadequate BP control to minimize, via the use of
low doses that carry a lower risk of side effects, the threat
of patient non adherence with the treatment regimen.68
Consequently, less frequent dosing regimens (ideally once
daily) combined with a favorable tolerability profile re-
sults in better medication-taking behavior.69–71 Indeed, the
availability of antihypertensive agents such as ARB,
which have proven efficacy and excellent tolerability, has
demonstrated that the selection of drugs with more favor-
able side effect profiles results in improved medication-
taking behavior. Data from a large pharmacy database in
the United States, for example, showed that patients
treated with ARB had greater medication persistence rates
at 1 year than those treated with other classes of antihy-
pertensive agents.69 Similar findings were apparent in a
more recent analysis of German prescriptions claims data,
in which persistence and adherence rates were signifi-
cantly higher for ARB such as valsartan compared with all
other drug classes.72 In another pharmacy system database
study of nearly 143,000 patients, significantly more pa-
tients taking valsartan remained persistent on therapy at 12
months (63%) compared with patients taking amlodipine
(53%) or lisinopril (50%) (P  .001)73 (Fig. 3). The
benefits of ARB for improving medication-taking behav-
ior have been confirmed in other studies74–76 and are
presumably explained by the combination of favorable
tolerability and once-daily dosing provided by these
agents. It is important to note that treatment choice is also
dependent on other key factors specific to each patient.
Conclusion
Treatment efficacy alone is not sufficient if patients do not
take their medications properly and consistently—in the
case of hypertension, most likely for the rest of their lives.
Patients with hypertension who have poor medication-
taking behavior remain largely unrecognized and the de-
FIG. 3. Persistence with antihypertensive therapy in a usual-care
setting. Reproduced with permission from Ref. 73velopment of programs to detect these individuals and
1195AJH–November 2006–VOL. 19, NO. 11 MEDICATION ADHERENCE, PERSISTENCE, AND ANTIHYPERTENSIVE THERAPYsupport long-term adherence is an important issue. On the
basis of current literature and clinical experience, it ap-
pears that an effective, convenient drug regimen that is
relatively free of side effects, combined with a positive and
supportive approach to treatment, will therefore yield the
best results in terms of facilitating adherence and persis-
tence with antihypertensive therapy.
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